Whanin Pharm (016580) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Whanin Pharm (016580) has a cash flow conversion efficiency ratio of 0.006x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.38 Billion ≈ $1.61 Million USD) by net assets (₩421.01 Billion ≈ $285.31 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Whanin Pharm defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Whanin Pharm - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Whanin Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Whanin Pharm Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Whanin Pharm ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bogota Financial Corp
NASDAQ:BSBK
|
0.002x |
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
0.032x |
|
Tillys Inc
NYSE:TLYS
|
0.101x |
|
Spyrosoft Spólka Akcyjna
F:2NP
|
0.126x |
|
Severn Trent PLC
LSE:SVT
|
0.224x |
|
icad inc
NASDAQ:ICAD
|
0.002x |
|
Yi Jinn Industrial Co Ltd
TW:1457
|
-0.005x |
|
Chung Lien Transportation Co Ltd
TWO:5604
|
0.011x |
Annual Cash Flow Conversion Efficiency for Whanin Pharm (2009–2025)
The table below shows the annual cash flow conversion efficiency of Whanin Pharm from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Whanin Pharm.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩421.01 Billion ≈ $285.31 Million |
₩9.04 Billion ≈ $6.13 Million |
0.021x | -60.97% |
| 2024-12-31 | ₩376.00 Billion ≈ $254.81 Million |
₩20.69 Billion ≈ $14.02 Million |
0.055x | -15.01% |
| 2023-12-31 | ₩358.21 Billion ≈ $242.75 Million |
₩23.20 Billion ≈ $15.72 Million |
0.065x | +28.33% |
| 2022-12-31 | ₩333.93 Billion ≈ $226.30 Million |
₩16.85 Billion ≈ $11.42 Million |
0.050x | -54.67% |
| 2021-12-31 | ₩317.23 Billion ≈ $214.98 Million |
₩35.32 Billion ≈ $23.93 Million |
0.111x | +45.12% |
| 2020-12-31 | ₩296.60 Billion ≈ $201.00 Million |
₩22.75 Billion ≈ $15.42 Million |
0.077x | -14.86% |
| 2019-12-31 | ₩274.46 Billion ≈ $186.00 Million |
₩24.73 Billion ≈ $16.76 Million |
0.090x | +34.01% |
| 2018-12-31 | ₩259.58 Billion ≈ $175.92 Million |
₩17.45 Billion ≈ $11.83 Million |
0.067x | -30.39% |
| 2017-12-31 | ₩243.08 Billion ≈ $164.73 Million |
₩23.48 Billion ≈ $15.91 Million |
0.097x | +7.26% |
| 2016-12-31 | ₩220.13 Billion ≈ $149.18 Million |
₩19.82 Billion ≈ $13.43 Million |
0.090x | -30.67% |
| 2012-12-31 | ₩162.53 Billion ≈ $110.14 Million |
₩21.11 Billion ≈ $14.31 Million |
0.130x | +28.78% |
| 2011-12-31 | ₩149.85 Billion ≈ $101.55 Million |
₩15.12 Billion ≈ $10.24 Million |
0.101x | -41.22% |
| 2009-12-31 | ₩108.44 Billion ≈ $73.49 Million |
₩18.61 Billion ≈ $12.61 Million |
0.172x | -- |
About Whanin Pharm
Whan In Pharm Co.,Ltd. manufactures and sells various pharmaceutical products in South Korea. The company offers products, such as gastrointestinal, respiratory, cardiovascular, antidiabetic, antibiotic, antifungal, antihistamine, antiviral, antirheumatic, muscle relaxant, nonsteroidal anti-inflammatory, smoking cessation, erectile dysfunction, prostate disease, urinary disorder, osteoporosis, an… Read more